ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "HLA antibodies"

  • 2020 American Transplant Congress

    Epitope Analysis of Complement-Binding De Novo Donor-Specific HLA Class II Antibody

    K. Yamanaka, M. Hashimoto, T. Kinoshita, Y. Fujita, S. Matsumura, T. Imanaka, A. Taniguchi, T. Yoshida, H. Kishikawa

    Department of Kidney Transplantation Center, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan

    *Purpose: Patients with de novo donor specific antibody (dnDSA) after kidney transplantation have a poorer prognosis than patients without dnDSA. Meanwhile, patients with dnDSA do…
  • 2020 American Transplant Congress

    Comparison of 1-Year Incidence of De Novo Donor Specific Antibodies between Thymoglobulin and Alemtuzumab Induction in Kidney Transplantation

    J. P. Knorr, C. Kallis, D. A. Portley, A. Jeyarajasingam, P. W. Lai, G. Bradauskaite, K. Khanmoradi

    Transplant Nephrology, Einstein Medical Center, Philadelphia, PA

    *Purpose: Development of de novo donor specific antibodies (dnDSA) after kidney transplantation (KTx) has been associated with acute and chronic antibody-mediated rejection, transplant glomerulopathy and…
  • 2020 American Transplant Congress

    De Novo DSA in the Setting of Stable Renal Allograft Function Does Not Impair Long-Term Graft Survival

    R. Knight1, D. T. Nguyen2, E. A. Graviss2, O. Gaber1

    1Surgery, Houston Methodist Hospital, Houston, TX, 2Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX

    *Purpose: To determine the long-term outcome of renal allograft recipients with de novo DSA (dnDSA) in the setting of stable allograft function.*Methods: A single-center review…
  • 2020 American Transplant Congress

    The Impact of Epitope Mismatch Load and Shared Targeting Epitopes between De Novo Donor Specific Antibody (DSA) and Non-DSA Third Party HLA Antibody on Lung Transplantation Outcomes

    A. Zhang1, D. Good1, D. Thomas1, J. Allen1, K. McCurry2, M. Budev2

    1Allogen Laboratories, Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH

    *Purpose: Rapid advancements in HLA typing and antibody identification technologies allow for enhanced HLA compatibility assessment at the epitope level to aid in the reduction…
  • 2020 American Transplant Congress

    Are HLA-DQ De Novo Donor-Specific Antibodies a Risk Factor for Acute Humoral Rejection?

    R. Hod Dvorai1, C. A. Hubbell1, M. R. Laftavi2, R. Shahbazov2, B. Gallay3, O. G. Pankewycz3

    1Pathology, SUNY Upstate Medical University, Syracuse, NY, 2Surgery, SUNY Upstate Medical University, Syracuse, NY, 3Medicine, SUNY Upstate Medical University, Syracuse, NY

    *Purpose: To identify HLA-DQ de novo donor-specific antibodies (dnDSA) characteristics associated with acute humoral rejection (ABMR) and response to treatment.*Methods: We performed a retrospective analysis…
  • 2020 American Transplant Congress

    Mid-Term Outcomes after Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?

    M. Okada1, T. Tomosugi1, T. Hiramitsu1, S. Narumi1, Y. Watarai1, A. Kanda1, K. Futamura1, N. Goto1, A. Takeda2

    1Nagoya Daini Red Cross Hospital, Nagoya, Japan, 2Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan

    *Purpose: De novo donor-specific HLA antibody (DSA) and antibody-mediated rejection (ABMR) are strongly associated with late allograft loss in renal transplant recipients. However, the impact…
  • 2020 American Transplant Congress

    Clazakizumab (Anti-IL-6) Induces Foxp3+ Tregs in Highly HLA Sensitized Patients Desensitized for HLAi Transplantation (NCT03380962)

    S. C. Jordan, S. Ge, N. Ammerman, M. Toyoda, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamson, C. Myers, K. Lim, J. Choi, A. Vo

    Cedars Sinai Medical Ctr, West Hollywood, CA

    *Purpose: Interleukin-6 is an important inflammatory cytokine. In addition, it acts as a growth factor for B-cells, plasma cells and Th17 cells, inhibiting FoxP3+ Treg…
  • 2020 American Transplant Congress

    Molecular Features of HLA Mismatches as Predictors of De Novo DSA Development: A Single Center Experience

    V. Jucaud1, L. Rebellato2, K. Briley2, C. Haisch2, S. Kendrick3, H. Jones3, K. Mclawhorn3, D. Leeser2, M. Everly1

    1Terasaki Research Institute, Los Angeles, CA, 2East Carolina University, Greenville, NC, 3Eastern Nephrology Associates, Greenville, NC

    *Purpose: Several molecular features (MoFs) of HLA mismatches (MMs) are currently used to predict the development of de novo donor-specific anti-HLA antibodies (dnDSA). The purpose…
  • 2020 American Transplant Congress

    Preformed Anti-HLA Donor-Specific Antibodies Immunological Risk Assessment: The Importance of HLA Antibody Locus-Specificity

    V. Jucaud1, A. Babu2, D. Briggs3, N. Krishnan4, D. Mitchell5, M. Everly1

    1Terasaki Research Institute, Los Angeles, CA, 2University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, 3NHS Blood and Transplant, Birmingham, United Kingdom, 4University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, 5University of Warwick Medical School, Coventry, United Kingdom

    *Purpose: The screening of preformed donor-specific HLA antibodies (pfDSA) by single antigen bead assays has increased the complexity of pre-transplant patient risk stratification. We evaluated…
  • 2020 American Transplant Congress

    The Art Rather Than the Science of Non-HLA Antibody Mediated Rejection in Heart Transplantation: A Single Center Experience

    A. Alam, S. Mckean, R. Patel, V. Darst, H. Zafar, C. Guerrero, M. Askar, T. Sam, S. Hall

    Cardiology, Baylor University Medical Center, Dallas, TX

    *Purpose: The role of non-HLA antibodies (Ab) in HLA-DSA negative antibody mediated rejection (AMR) following heart transplant (HTx) remains largely unknown.*Methods: Retrospective analysis of all…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 47
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences